Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies and tends to be relatively resistant to conventional therapies. Activated Ras oncogene mutations are found in up to 90% of PDAC, leading to activation of the Ras/Raf/MEK/ERK signaling pathway. Sorafe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Awasthi, Niranjan, Zhang, Changhua, Hinz, Stefan, Schwarz, Margaret A, Schwarz, Roderich E
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3618297/
https://ncbi.nlm.nih.gov/pubmed/23497499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-32-12
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars